---
title: "Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2026 Q1 Revenue: USD 16.04 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286464954.md"
datetime: "2026-05-14T20:36:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286464954.md)
  - [en](https://longbridge.com/en/news/286464954.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286464954.md)
---

# Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2026 Q1 Revenue: USD 16.04 M

Revenue: As of FY2026 Q1, the actual value is USD 16.04 M.

EPS: As of FY2026 Q1, the actual value is USD 2.82.

EBIT: As of FY2026 Q1, the actual value is USD -4.941 M.

#### Net Income

Fortress Biotech-优先股 A’s consolidated net income attributable to common stockholders was $108.4 million for the first quarter ended March 31, 2026, significantly increasing from a net loss of - $12.7 million for the same period in 2025 .

#### Revenue

Consolidated net revenue totaled $16.0 million for the first quarter ended March 31, 2026, up from $13.1 million in the first quarter of 2025 . **Journey Medical Product Revenue**: Net product revenues from Journey Medical’s marketed dermatology products were $15.9 million for the first quarter of 2026, compared to $13.1 million for the first quarter ended March 31, 2025 . **Cyprium Royalty Revenue**: Cyprium recognized $0.1 million in royalty revenue on net sales of ZYCUBO® in the first quarter of 2026 .

#### Operational Costs

-   **Research and Development Expenses**: Consolidated research and development expenses decreased to $0.5 million for the first quarter of 2026, from $3.9 million for the same period in 2025 .
-   **Selling, General and Administrative Costs**: Consolidated selling, general and administrative costs were $15.9 million for the first quarter of 2026, down from $25.7 million for the first quarter of 2025 .
-   **Cost of Goods (excluding amortization)**: Cost of goods was $6.218 million for the first quarter of 2026, compared to $4.790 million for the first quarter of 2025 .
-   **Amortization of Acquired Intangible Assets**: Amortization expenses were $1.126 million for the first quarter of 2026, compared to $1.065 million for the first quarter of 2025 .

#### Operating Profit

Loss from operations improved to - $7.739 million for the first quarter of 2026, from - $22.317 million for the first quarter of 2025 .

#### Cash and Cash Equivalents

Fortress Biotech-优先股 A’s consolidated cash and cash equivalents significantly increased to $255.8 million as of March 31, 2026, from $79.4 million as of December 31, 2025 . This includes $209.9 million attributable to Fortress Biotech-优先股 A and private subsidiaries, $2.4 million to Avenue, $16.3 million to Mustang Bio, and $27.2 million to Journey Medical as of March 31, 2026 .

#### Unique Financial Metrics

-   **Gain on Sale of Priority Review Voucher (PRV)**: Fortress Biotech-优先股 A recognized a gain of $158.873 million from the sale of a PRV, net of expenses, in the first quarter of 2026 . Cyprium Therapeutics closed the sale of its PRV for gross proceeds of $205 million in March 2026 .
-   **Debt Reduction**: Fortress Biotech-优先股 A made aggregate prepayments on its loan with Oaktree in March 2026, reducing the outstanding principal balance to $15.0 million . Long-term notes payable, net, decreased to $36.878 million as of March 31, 2026, from $52.417 million as of December 31, 2025 .

#### Outlook / Guidance

Fortress Biotech-优先股 A expects increasing royalty revenue from ZYCUBO® and UNLOXCYT™, alongside potential milestone payments across its portfolio . AstraZeneca’s regulatory submissions in the EU and Japan for anselamimab (formerly CAEL-101) are anticipated to lead to potential future sales milestones for Fortress Biotech-优先股 A and approval milestones in the U.S. . Avenue plans to meet with the FDA in 2026 to discuss the design of a potential single pivotal trial for ATX-04 for Pompe disease .

### Related Stocks

- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Adamas Trust, Inc. 6.875% PFD SER F declares $0.4297 dividend](https://longbridge.com/en/news/289515541.md)
- [Bitmine Immersion Technologies Announces Pricing of Upsized Series A Perpetual Preferred Stock Offering | BMNP Stock News](https://longbridge.com/en/news/288862382.md)
- [Modiv Inc. 7.375% CUM SER A declares $0.4609 dividend](https://longbridge.com/en/news/289467548.md)
- [Cherry Hill Mortgage Investment Corporation Announces Common and Preferred Dividends for the Second Quarter 2026 | CHMI Stock News](https://longbridge.com/en/news/289510631.md)
- [New York Mortgage Trust Cum Conv Perp Red Pfd Registered Shs Series D declares $0.50 dividend](https://longbridge.com/en/news/289515567.md)